Intelligent Bio Solutions Inc. (Intelligent Bio Solutions) has entered into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. (Ladenburg) on September 18, 2024, to offer and sell shares of its common stock with an aggregate offering price of up to $3,000,000. The shares will be offered through Ladenburg, acting as a sales agent or principal. Intelligent Bio Solutions is classified as an 'emerging growth company' and 'smaller reporting company' under U.S. federal securities laws, subject to reduced public company reporting requirements. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'INBS', with the last sale price on September 16, 2024, being $2.24 per share. The offering may be made in 'at the market offerings' as defined...Show More

Intelligent Bio Solutions Inc. (Intelligent Bio Solutions) has entered into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. (Ladenburg) on September 18, 2024, to offer and sell shares of its common stock with an aggregate offering price of up to $3,000,000. The shares will be offered through Ladenburg, acting as a sales agent or principal. Intelligent Bio Solutions is classified as an 'emerging growth company' and 'smaller reporting company' under U.S. federal securities laws, subject to reduced public company reporting requirements. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'INBS', with the last sale price on September 16, 2024, being $2.24 per share. The offering may be made in 'at the market offerings' as defined in Rule 415 under the Securities Act of 1933. Ladenburg will use commercially reasonable efforts to sell the shares, and the compensation to Ladenburg will be 3.0% of the gross proceeds from any shares sold under the agreement, in addition to reimbursement of certain expenses. Intelligent Bio Solutions has also agreed to provide indemnification and contribution to Ladenburg with respect to certain liabilities. As of September 16, 2024, the aggregate market value of the company's non-affiliate shares was $9.45 million, based on 4,249,782 outstanding common stock shares. The company has not sold any securities pursuant to General Instruction I.B.6 of Form S-3 in the 12 months prior to the prospectus supplement date. Investing in the company's securities involves a high degree of risk, and the Securities and Exchange Commission has not approved or disapproved the securities or passed upon the adequacy or accuracy of the prospectus supplement.